Search Encephalitis.info


Thank You For Your Feedback

If you have any additional comments about the information on this page, please let us know.



We've just launched our new website!


Our new site has just launched, and some of the pages are currently still under construction.

We thank you for your patience, please don't hesitate to contact us if you have any questions or queries.

  • Support line: +44 (0)1653 699599
  • Contact Us
ArrowArrow

Hannibal and The Society

Hannibal_logo.jpg

To celebrate the release of the Season 3  of Hannibal on DVD, The Encephalitis Society has collaborated with the team behind the show to tell you a bit more about encephalitis - in particular the type that affected Will Graham.

We are a global organisation which supports those left devastated and bereaved by the condition – and we hope this World Encephalitis Day - February 22 that Fannibals from around the world will help us by spreading the message about encephalitis to their friends and families. We would like you to #ShowYouKnow about encephalitis by wearing #RED4WED - you can buy our campaign t-shirt online by clicking on the image below. Alternatively wear something blood red and make a donation here

Make sure you take a selfie and share with us via our Facebook or Twitter  @encephalitis accounts! #ShowYouKnow #RED4WED

World_Encephalitis_Day_Tee_Front.jpg

Will_GRaham.jpgWill Graham and NMDA Receptor Antibody Encephalitis.

In Hannibal, Will Graham was affected by NMDA-Receptor Antibody Encephalitis, also known as Anti-NMDA Receptor Encephalitis.

And, just as in the majority of real-life cases, he displayed disturbing psychiatric behaviour, including hallucinations and disorientation.

Here experts Dr Sarosh R Irani and Professor Angela Vincent, of John Radcliffe Hospital, Oxford, give a breakdown of the condition.

What is NMDA-Receptor Antibody Encephalitis?

The major role of our immune system is to recognise and get rid of infection. But sometimes some components of the immune system, called antibodies, may instead react with proteins in our own body causing an autoimmune disease. When this reaction is against proteins in the brain it is called Autoimmune Encephalitis.

Many cases of Autoimmune Encephalitis associated with antibodies against the N-methyl D-aspartate (NMDA) receptor have recently been reported.

 NMDA receptor is a protein in the brain that helps control the electrical activity of nerves and therefore antibodies against these receptors are likely to have an important role in directly causing the disease.

Diagnosis

The symptoms and signs seen in patients with NMDA Receptor Antibody associated Encephalitis can be distinctive and are prompting many clinicians to request the NMDA receptor antibody test to diagnose this condition. The disease mainly affects young people, with around 30% of cases under 18 years of age. Women are affected more often than men.

Symptoms

At onset, the most distinctive features include prominent psychiatric symptoms, seizures, confusion and memory loss. Patients will sometimes show bizarre and often rather disturbing behaviours. Typically 10 to 20 days later, patients develop a movement disorder, variations in blood pressure, heart rate and temperature and may become less conscious. The movement disorder often consists of continuous writhing and twitching of face and limbs but can also be a generalised slowing-down of movement. More recently, patients with only a few of these features have been recognized to have NMDA-receptor antibodies.

Treatment

Treatment consists of immune therapies and removal of a tumour, if present. The immune therapies use medicines to dampen down the immune system. These include steroids, immunoglobulins (a blood product given into the vein in a drip) and plasma exchange (when some of a person’s blood is taken out from a vein, washed and then put back into the vein in a drip). In addition, some patients are treated with other drugs which dampen down the immune system. All drugs have known side-effects but their benefits are generally felt to outweigh possible side-effects.

Prompt therapies offer a good chance of substantial recovery in the majority of patients. As they improve there is often a reduction in the amount of NMDA receptor antibody in the person’s blood when the test is repeated. Some patients are now being treated after recognition of the clinical symptoms and signs, while the antibody result is awaited, to try to improve recovery. However, recovery is usually slow and many patients spend a few months in hospital, including time on the intensive care unit undergoing ventilation. Those who return to work typically only do so after a year or two.

In summary, NMDA Receptor Antibody Encephalitis is a recently identified autoimmune disease that causes psychiatric features, confusion, memory loss and seizures followed by a movement disorder, loss of consciousness and changes in blood pressure, heart rate and temperature. The disease can respond well to various therapies that dampen down the immune system and the removal of an underlying tumour if one is found, but improvement is often slow.

Susannah Cahalan

CahalanSusannah.jpgNew York Journalist Susannah Cahalan’s account of her battle with Anti-NMDA Encephalitis resulted in the New York Times bestselling book, Brain on Fire: My Month of Madness.

Susannah has since become an Ambassador with The Encephalitis Society and our chief supporter in the United States of America.

A big screen version of Brain on Fire will be released in 2016, starring Chloe Grace-Moretz and Richard Armitage, who we are sure Hannibal fans will be all too familiar with!

Click on the video below to hear Susannah speak about her experiences.

We have limited edition signed copies of Brain on Fire: My Month of Madness available from www.encephalitisshop.com - get your copy today!

For more about Susannah, visit www.susannahcahalan.com

You must install Adobe Flash to view this content.

The Encephalitis Society is the operating name of the Encephalitis Support Group which is a registered Charity and Company Limited by Guarantee.

Registered in England and Wales No. 4189027. Registered Office as above. Registered Charity No. 1087843.